- TVS Cipher Network Adds Lights Out,Foreign Intrigue,Science Fiction Theater to WatchYour.TV Platform
- TVS Nostalgia TV Network Adds My World and Welcome to It to Winter 2022 WatchYour.TV Schedule
- Cpics - A New Streaming Platform Dedicated to South Asian Content Announce Upcoming 2022 Activities
The ODD is expected to accelerate the registration and launch of CT120 in the United States, where the product will be eligible to several preferential policies, including FDA support for clinical research, a waiver or reduction of certain fees, and seven years marketing exclusivity upon product approval.
The ODD is based on the proven clinical safety and efficacy of CT120. In an investigator-initiated clinical study (Registration No: ChiCTR2000038641), all 4 subjects with B-cell ALL achieved complete response (CR) after treatment with CT120 treatment, with a complete remission rate (CRR) of 100%. No Grade 3 or higher cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) was observed. Based on these results, CT120 is expected to become an innovative treatment for patients with relapsed/refractory B-ALL.
Dr. Wen (Maxwell) Wang, CEO of IASO Bio said, "CT120 is the first dual-targeted CAR-T cell therapy. The ODD granted to CT120 demonstrates the FDA's recognition and expectation of the product. CT120 has obtained two IND approvals for B-NHL and B-ALL in China, and the clinical trial for the treatment of B-NHL is going well. The company is advancing the development of the product in China and United States. We look forward to the launch of this innovative therapy to cure more patients."
More on The Californer
- 1017 Brick Squad Records 2022 New Artist Acquisition
- Strategic Benefits Advisors, Inc. Data Breach Triggers Investigation into Class Action Lawsuit
- San Francisco Extends Funding for Right to Recover Program to Support COVID-Positive Workers
- BetterHelp Partners with The Hidden Dream to Support Immigrant Communities
- San Francisco: Mayor London Breed Announces Opening of Bayview Vehicle Triage Center
About the FDA's Orphan Drug Designation
The Orphan Drug Designation (ODD) is granted by the FDA's Office of Orphan Products Development (OOPD) to eligible drugs (including biologic agents) for the prevention, treatment, and diagnosis of rare diseases. The FDA defines rare diseases as those which affect fewer than 200,000 people in the United States. Due to the small number of patients, low market demand and huge R&D costs, pharmaceutical companies were less inclined to invest in the development of these drugs without specific policy support. In 1983 however, the United States Congress passed the Orphan Drug Act (ODA), stipulating that all drug candidates granted the ODD will have access to a series of supporting policies.
Acute lymphoblastic leukemia (ALL) is a rapidly progressing form of leukemia and is a cancer of the blood and bone marrow, which can occur in both adults and children. According to the SEER in the United States, the annual incidence of ALL is 1.8 per 100,000, the mortality rate is 0.4 per 100,000, and the five-year survival rate is 69.9%. Based on these figures, the number of patients with ALL in the United States in 2021 is estimated at 115,000. According to the Frost & Sullivan report, the five-year survival rate of leukemia patients in China is only 25.4%, which is significantly lower than that in the United States. In 2020, the number of new ALL cases in China was 12,800, and the total number of patients with ALL was 143,900, and it is expected to rise to 150,300 in 2025.
CT120 is an autologous dual-target CAR-T therapy. Its extracellular domain contains two fully human single-chain fragment variable (scFv) sequences that can specifically bind to CD19 and CD22, identifying tumor cells with CD19 and CD22 expressions, thereby reducing the tumor escape caused by the loss of target antigen. Adopting a fully human design, CT120 has low immunogenicity, reduces the ADA effect, and improves CAR-T cells' viability.
More on The Californer
- California: Governor Newsom Statement on December Jobs Report
- Long-Term Care Insurance Claims Paid Data Shared By Association
- Sweet Flower, Los Angeles' Largest Owned and Operated Retailer, Launches Flagship Store in Culver City and Announces Record 2021 Results
- A. Barry Cappello and Leila Noël Selected to 2022 Southern California Super Lawyers List
- Franklin Limited Duration Income Trust ("FTF" or the "Fund") Announces Distribution
Compared to the intracellular costimulatory signal CD28, CT120's intracellular costimulatory signal 4-1BB and CD3ζ have lower neurotoxicity and improved viability of CAR-T cells, thus more durable efficacy. Upon binding with CD19/CD22 antigens on the tumor cells, CT120 eliminates targeted tumor cells through the release of granzyme and perforin while simultaneously releases cytokine to promote the proliferation of CAR-T cells, thus achieves its durable antitumor activity.
About IASO Bio
IASO Bio is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and autoimmune diseases. Leveraging its proprietary fully human antibody discovery platform (IMARS), high-throughput CAR-T drug priority platform, and proprietary manufacturing processes, IASO Bio is developing a rich clinical-stage pipeline of multiple autologous and allogeneic CAR-T and biologics product candidates. This includes a diversified portfolio of 10 novel pipeline products, including IASO's leading asset, CT103A, an innovative anti-BCMA CAR-T cell therapy under pivotal study for relapsed/refractory (R/R) multiple myeloma (RRMM). CT103A received Breakthrough Therapeutic Designation by China's National Medical Products Administration (NMPA) in February 2021. In addition, the company's in-house developed fully human CD19/CD22 dual-targeted chimeric antigen receptor (CAR)-T cell therapy has entered phase I/II registrational clinical trial for the treatment of CD19/CD22-positive relapsed/refractory B-cell non-Hodgkin's lymphoma (r/r B-NHL). It has also received IND clearance from NMPA for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL). For more information on IASO Bio, please visit www.iasobio.comand or LinkedIn.
SOURCE IASO Biotherapeutics
Filed Under: Business
Latest on The Californer
- "Bliss Brain" Wins the Nautilus and American Book Fest Top Awards
- Insurance Association Launches 2022 Selling Medicare Insurance Video Package
- TEAMSTERS STAGE PRACTICE PICKET AT CEMEX
- Console & Associates, P.C. Investigates Class Action Lawsuit Following LendUS, LLC Data Breach
- ReoStar Energy Corporation Executes Letter of Intent (LOI) with an experienced oil and gas company
- CORRECTING and REPLACING PHOTO Open Influence Launches Go Prism Self-Serve SaaS Solution, an Innovative Influencer Marketing and Insights Tool for Social Media Marketers
- Yunishigawa Onsen's Kamakura Festival Features the Unique Northern Japan Winter Tradition: Kamakura or Snow Huts
- A New Social Network Based on Gratitude and Positivity
- Prophecy Raises $25M to Accelerate Availability of Its Low-Code Platform for Data Engineering
- Alten Construction completes modernization of Castro Valley High School
- We Are Reaching Out to Our Community in Los Angeles
- Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Volkswagen AG (VWAGY)
- Five Tips To Keep Your Employees Happy
- Raleigh Business Leader Joins 2022 National Small Business Association Board Leadership
- Edge2Learn Premieres Its Integrative Multifamily Policy and Procedure Product
- 2022 Southern California Super Lawyers Recognizes Four California Snell & Wilmer Partners
- San Jose: : New Animals Fly Into the Coop at Happy Hollow's Double-H Ranch
- Former BIS Special Agent Donald Pearce Joins Torres Trade Advisory
- Alcor announces the launch of new AccessFlow release, an IAM solution that provides automated, centralized, and compliant Access Management
- FuseFX Promotes Johnny Fisk to President